shutterstock_634058222_sergiy_palamarchuk

Sergiy Palamarchuk / Shutterstock.com

8 July 2021Big PharmaAlex Baldwin

Poland’s Polpharma asks US court to grant Swiss arbitration in TS case

Poland’s largest pharmaceutical company has asked the federal court to let it pursue arbitration in a Swiss court for a trade secrets dispute between India’s Rubicon Research and North Carolina biotech firm Kartha Pharmaceuticals.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

The European take on the Bolar provision: conclusions from Astellas v Polpharma

1 April 2013 While changes to European law seem to allow fairly broad exemptions to the patent law for companies developing generic alternatives to branded drugs, the reality is different, as Rafał Witek explains.

US court resolves muscle relaxant dispute by enforcing arbitration award

20 July 2023 Polpharma’s injunction bid fails as motion is dismissed with prejudice | Court upholds Swiss Arbitration process.

More on this story

The European take on the Bolar provision: conclusions from Astellas v Polpharma

1 April 2013 While changes to European law seem to allow fairly broad exemptions to the patent law for companies developing generic alternatives to branded drugs, the reality is different, as Rafał Witek explains.

US court resolves muscle relaxant dispute by enforcing arbitration award

20 July 2023 Polpharma’s injunction bid fails as motion is dismissed with prejudice | Court upholds Swiss Arbitration process.

More on this story

The European take on the Bolar provision: conclusions from Astellas v Polpharma

1 April 2013 While changes to European law seem to allow fairly broad exemptions to the patent law for companies developing generic alternatives to branded drugs, the reality is different, as Rafał Witek explains.

US court resolves muscle relaxant dispute by enforcing arbitration award

20 July 2023 Polpharma’s injunction bid fails as motion is dismissed with prejudice | Court upholds Swiss Arbitration process.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent